Driven to fundamentally change the industry, EmpiRx Health is the most clinically advanced and only value-based pharmacy benefits manager (PBM).
Founded in 2014, the company’s growth is fueled by the highly unique, client-aligned nature of its value proposition – a pay-for-performance financial model with guaranteed savings, the industry’s first client-tailored population health management solution, and an unparalleled high-touch service experience resulting in industry-best client retention rates.
EmpiRx Health is a category creator, redefining the traditionally volume-oriented healthcare benefits model through its value-based approach. By embracing a practical Population Health Management model that places pharmacists at the center of patient care teams, EmpiRx Health optimizes both patient health and financial outcomes.
With total client savings now north of $1 billion dollars, new EmpiRx Health clients see an average of 15% reduction in their per member per month costs (PMPM) and sustained savings year-over-year.
EmpiRx Health’s proprietary technology—powered by The Johns Hopkins ACG, AI, and machine learning— generates deep insights into the risk profile of every patient population; clients receive customized clinical strategies for their unique membership.
This strategy, paired with pharmacist-physician engagement, allows its clinicians to identify gaps in care and address health inequities, improving outcomes and lowering costs.
As an example, EmpiRx Health recently partnered with the UCFW National Health and Welfare Fund to create a high-touch care model for members with complex healthcare needs.
A dedicated Member Care Advocate (MCA) is now embedded within the Fund’s benefits team, providing members with the greatest care needs the expertise of a certified clinician who serves as a clinical and benefits concierge on their behalf.
This role takes EmpiRx Health’s promise to deliver proactive, tailored service one step further, mirroring the passion that UFCW members bring to their jobs.
Takeaway: EmpiRx Health is redefining healthcare by proving it is possible to control drug spend while improving health outcomes
AMI’s 2023-2024 PBM Review profiles more than 60 PBM companies. The report identifies and segments the market into Market Leaders, Mid-Market PBMs, and Non-Traditional PBMs. AMI’s report also provides a brief background on the market. Each PBM company profile includes: company background, strategy, key decision-makers, financial/investor information, products and services, and recent activities.